Clinical trial
Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma
NCT02692339 is registered in ClinicalTrials.gov with Celgene as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Prospective Observational Study Evaluating the Safety of Lenalidomide/Dexamethasone Treatment in Patients With Relapsed or Refractory Multiple Myeloma
- Lead sponsor
- Celgene
- Phase
- Observational
- Overall status
- Completed
- Start date
- February 25, 2016
- Completion date
- December 12, 2018
- Enrollment
- 22 (actual)
- Sites
- 12
Conditions
As the registry lists them; a condition with its own page is linked.